Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis

Stamatina Kanelli, Stephen M. Ansell, Thomas M. Habermann, David J. Inwards, Nancy Tuinstra, Thomas E. Witzig

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Infusion related adverse events (AE) with day 1 rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL) are common. The purpose of this study was to evaluate the AE occurring in patients with malignant B-cell lymphocytosis who received rituximab. Patients with a ≥ 3 × 109/L absolute lymphocyte count (ALC) receiving rituximab from 1998 to 1999 or participating in a phase I study of rituximab and interleukin-12 were reviewed. The AE occurring on the day of rituximab, the treatment provided (including hospitalization), and the subsequent ALC responses were recorded. Twenty-seven patients were identified; 14 had NHL, one Waldenstrom's macroglobulinemia, and 12 patients had chronic lymphocytic leukemia. The baseline median ALC was 9.58 × 109/L (mean, 49.31; range, 3.56-380.95). All patients received rituximab as an outpatient. There were only two AE ≥ grade 3. One patient was hospitalized for 1 day for IV fluids to treat an increase in creatinine that occurred with tumor lysis. A second patient developed a pulmonary syndrome five days after day 1 rituximab and required mechanical ventilation, but had no long-term lung toxicity. This study demonstrates that patients with high numbers of circulating blood B-lymphocytes can usually safely receive rituximab as outpatients. Patients who experience a rapid drop in ALC should be monitored closely for tumor lysis and the pulmonary syndrome.

Original languageEnglish (US)
Pages (from-to)1329-1337
Number of pages9
JournalLeukemia and Lymphoma
Volume42
Issue number6
DOIs
StatePublished - Dec 1 2001

    Fingerprint

Keywords

  • Chronic lymphocytic leukemia
  • Non-Hodgkin's lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this